TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9448552
Drug: Theophylline (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (dosage titrated to achieve trough concentrations of 8 to 15 micrograms/mL)
Study: 2615523
Drug: Morning intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning intravenous administration of 4' epi-adriamycin (45 mg m-2)
Study: 2615523
Drug: Afternoon intravenous
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Afternoon intravenous administration of 4' epi-adriamycin (45 mg m-2)
Study: 2615523
Drug: Morning and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning and afternoon dosing of 4' epi-adriamycin
Study: 21983248
Drug: TPA (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPA (25 μg)
Study: 21983248
Drug: IVB (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVB (1.25 mg of bevacizumab)
Study: 8285365
Drug: Ozone therapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone therapy (endovenous)
Study: 8285365
Drug: Ozone therapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone therapy (intramuscular)
Study: 8285365
Drug: Ozone therapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone therapy (rectal)
Study: 22921698
Drug: Daily vardenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily vardenafil 10 mg
Study: 18514907
Drug: Urtica dioica
Normalized name: Urtica Dioica
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urtica dioica (nettle sting) daily for 1 week
Study: 18514907
Drug: Urtica galeopsifolia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urtica galeopsifolia (placebo) daily for 1 week
Study: 15452188
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (40,000 U once weekly)
Study: 12616254
Drug: New MOW
Approvals — FDA: no, EMA: no, PMDA: no
Description: New MOW program (3 meals and 2 snacks per day, 7 days a week, meeting 100% of the Daily Reference Intake)
Study: 12616254
Drug: Traditional MOW
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional MOW program (5 hot meals per week, meeting 33% of the Daily Reference Intake)
Study: 26554025
Drug: Prasugrel (potent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (potent irreversible P2Y12 inhibitor)
Study: 18271227
Drug: Chinese drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese drugs acupoint injection (Danshen Injection and Chaihu Injection)
Study: 18271227
Drug: Saline acupoint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline acupoint injection
Study: 18271227
Drug: Huichun Ruyi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huichun Ruyi capsules
Study: 16302325
Drug: 1% clindamycin/zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% clindamycin/zinc gel applied once daily
Study: 16302325
Drug: 1% clindamycin/zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% clindamycin/zinc gel applied twice daily
Study: 16302325
Drug: 1% clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% clindamycin lotion applied twice daily
Study: 12044272
Drug: TyphimVi and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: TyphimVi and YF‐VAX on day 0 and an optional dose of VAQTA 1 month later (Group 2)
Study: 2508161
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg orally administered diazepam
Study: 202346
Drug: Clozapine 25
Normalized name: clozapine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine 25 mg/night for three consecutive nights
Study: 29976582
Drug: Alteplase treatment
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alteplase treatment decision based on NIHSS scores
Study: 29976582
Drug: Factors influencing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Factors influencing treatment decisions
Study: 22892110
Drug: Nitrofurantoin 100
Normalized name: nitrofurantoin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrofurantoin 100 mg twice a day for 5 consecutive days
Study: 22892110
Drug: Placebo 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 100 mg twice a day for 5 consecutive days
Study: 20706917
Drug: Panic Control
Normalized name: BENZALKONIUM CHLORIDE 1 g in 59 mL TOPICAL GEL [Donut Panic Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panic Control Treatment for Adolescents (PCT‐A)
Study: 17954368
Drug: Amlodipine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine alone after discontinuation of Quinapril for 6 weeks
Study: 16135167
Drug: N-acetylcysteine (352
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (352 mg per day)
Study: 16135167
Drug: Bromhexine hydrochloride
Normalized name: bromhexine hydrochloride
DrugBank: Bromhexine (DB09019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromhexine hydrochloride (4 mg per day)
Study: 23278355
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose of alcohol (breath alcohol concentration 50 mg/dl)
Study: 14992558
Drug: Oats-containing gluten-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oats-containing gluten-free diet (50 g daily)
Study: 10584476
Drug: Dexamethasone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.5 mg/kg/day for 5 days, tapered progressively)
Study: 28072459
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (CBT) alone
Study: 31318392
Drug: Durvalumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab plus tremelimumab combination therapy (1500 mg durvalumab every 4 weeks and 75 mg tremelimumab every 4 weeks for 4 cycles, followed by durvalumab monotherapy for up to 12 months)
Study: 31318392
Drug: Durvalumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab monotherapy (1500 mg every 4 weeks for up to 12 months)
Study: 17545007
Drug: No induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: No induction therapy
Study: 15716702
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day enalapril (ACE inhibitor)
Study: 10530414
Drug: Roquinimex (Linomide),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roquinimex (Linomide), 0.2 mg/kg body weight, twice weekly for 2 years
Study: 2031798
Drug: Sodium diatrizoate
Normalized name: Diatrizoate Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium diatrizoate (ionic monomer) at 150 mg I/ml (726 mosmol/kg)
Study: 29161417
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (50,000 IU oral weekly for 12 weeks)
Study: 29161417
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral weekly for 12 weeks)
Study: 26879279
Drug: AMG 334
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 334 70 mg
Study: 26879279
Drug: AMG 334
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 334 7 mg
Study: 26879279
Drug: AMG 334
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 334 21 mg
Study: 22339125
Drug: Darunavir/ritonavir (DRV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/ritonavir (DRV/r) 600/100 mg bid
Study: 22339125
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) 400/100 mg bid
Study: 20540443
Drug: Diazepam (5-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (5-40 mg) and Flumazenil (0.36 mg)
Study: 20540443
Drug: Flumazenil (0.36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.36 mg)
Study: 1483797
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg slow release every 8 hours)
Study: 6364778
Drug: Multiagent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiagent chemotherapy including cyclophosphamide, imidazolecarboxamide, and vincristine given in 5-day pulses each month for 12 courses.
Study: 6364778
Drug: Multiagent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiagent chemotherapy (as prescribed).
Study: 6364778
Drug: Previous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous treatment regimen from study CCG 011 (no chemotherapy or oral CPM).
Study: 22683137
Drug: Glimepiride once
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride once daily
Study: 15841092
Drug: Lactobacillus acidophilus
Normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus acidophilus (3 x 10^10 CFU, two capsules, three times a day for 6 weeks)
Study: 15841092
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two capsules, three times a day for 6 weeks)
Study: 12469331
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg albendazole
Study: 9585394
Drug: Fasting plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting plasma glucose > or = 10.0 mmol/l
Study: 9585394
Drug: Fasting plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting plasma glucose > or = 7.8 mmol/l to < 10.0 mmol/l
Study: 9585394
Drug: Fasting plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting plasma glucose < 7.8 mmol/l
Study: 2817307
Drug: Turbuhaler (terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turbuhaler (terbutaline inhalation)
Study: 2817307
Drug: Nebuhaler (terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebuhaler (terbutaline inhalation)
Study: 51664
Drug: Heparinoid cream
Normalized name: heparinoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparinoid cream
Study: 31492999
Drug: Assessment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment of supplement samples
Study: 27879193
Drug: Flumagen® 370
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumagen® 370 mg tablet
Study: 27879193
Drug: Somalgen® 370
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somalgen® 370 mg tablet
Study: 25389489
Drug: Oral education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral education program
Study: 17575467
Drug: Losartan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (100 mg/day) + Pioglitazone (30 mg/day)
Study: 8961475
Drug: Dexamethasone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (20 mg) in addition to ondansetron (8 mg three times a day)
Study: 8961475
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in addition to ondansetron (8 mg three times a day)
Study: 1742515
Drug: nizatidine 150
Normalized name: nizatidine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nizatidine 150 mg
Study: 7342331
Drug: Praziquantel 25
Normalized name: PRAZIQUANTEL 25 kg in 25 kg POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel 25 mg per kg body weight bid for one day (Group III)
Study: 7342331
Drug: Praziquantel 25
Normalized name: PRAZIQUANTEL 25 kg in 25 kg POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel 25 mg per kg body weight in a single dose (Group IV)
Study: 7342331
Drug: Praziquantel 40
Normalized name: PRAZIQUANTEL 40 mg in 1 mL ORAL SOLUTION [A Vial]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel 40 mg per kg body weight in a single dose (Group V)
Study: 26761398
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy sessions analysis
Study: 22630801
Drug: Cognitive remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive remediation (CR) therapy (12 sessions of computer-assisted CR)
Study: 22630801
Drug: Cognitive remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive remediation (CR) therapy
Study: 12523867
Drug: Testosterone cypionate
Normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone cypionate 100 mg/week
Study: 12523867
Drug: Testosterone cypionate
Normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone cypionate 200 mg/week
Study: 9155505
Drug: Selenomethionine (SeMet)
Normalized name: selenomethionine
DrugBank: Selenomethionine (DB11142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selenomethionine (SeMet) 200 micrograms daily
Study: 9155505
Drug: Selenate (Se-enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenate (Se-enriched yeast) 200 micrograms daily
Study: 3612550
Drug: Domperidone (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (0.4 mg/kg)
Study: 29243443
Drug: CC+Gn+Dingkun Dan
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC+Gn+Dingkun Dan
Study: 29243443
Drug: CC+Gn+HCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC+Gn+HCG
Study: 25205409
Drug: US-guided single-injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: US-guided single-injection femoral nerve block with 40 ml of 0.5% bupivacaine and 1:200,000 epinephrine (Group F)
Study: 23060723
Drug: Macular laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macular laser photocoagulation following intravitreal injection of triamcinolone acetonide (IVTA)
Study: 23060723
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of triamcinolone acetonide (IVTA) alone
Study: 20214324
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium dual release enteric-coated capsules and Benzbromarone (Control)
Study: 14985171
Drug: Platelet-neutrophil conjugate
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-neutrophil conjugate formation induced by thrombin receptor activating peptide (TRAP)
Study: 7512299
Drug: Three TUHT
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three TUHT treatments
Study: 7512299
Drug: Six TUHT
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six TUHT treatments
Study: 1320621
Drug: 1.5 mm
Normalized name: blade lancet, safety 1.5 mm X 2 mm MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mm intramedullary rod (polyglycolide implants)
Study: 82735
Drug: Enkephalin analogue
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enkephalin analogue [D‐Ala2, MePhe4, Met(o)‐ol] enkephalin (DAMME) administered intravenously
Study: 82735
Drug: Prior administration
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior administration of the opiate antagonist, naloxone
Study: 21303403
Drug: Systemic amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic amoxicillin (AMX) 500mg + metronidazole (MET) 250mg, t.i.d. for 10 days
Study: 17122107
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg lutein
Study: 17122107
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg lutein
Study: 17478338
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg lutein
Study: 17122107
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of lutein
Study: 2962529
Drug: Thiamphenicol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamphenicol 2.5 g orally
Study: 2962529
Drug: Spectinomycin 2
Normalized name: spectinomycin 2 g intramuscular powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spectinomycin 2 g intramuscularly
Study: 24094979
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care plus cognitive-behavioral therapy (STD + CBT)
Study: 12243656
Drug: 10 cc
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 cc of 2% intrarectal lidocaine gel (Xylocaine 2% jelly, Astra Pharma Inc.) 5 to 10 minutes before the procedure
Study: 12243656
Drug: 10 cc
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 cc of lubricating gel
Study: 2305099
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL of contrast material injected at the level of the external iliac artery (EIA)
Study: 2305099
Drug: 60 mL
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mL of contrast material injected at the level of the EIA
Study: 2305099
Drug: 120 mL
Normalized name: 120 ML Infugem 10 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mL of contrast material injected at the level of the aortic bifurcation and 60 mL injected at the level of the EIA
Study: 2305099
Drug: 60 mL
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mL injected at the level of the EIA with inflow occlusion
Study: 2305099
Drug: 60 mL
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mL injected at the level of the EIA without inflow occlusion
Study: 7005123
Drug: Furosemide +
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide + Triamterene (80 + 100 mg)
Study: 28338504
Drug: Protective group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protective group (tidal volume; 6 mL/kg predicted body weight, 6 cm H2O positive end-expiratory pressure with recruitment maneuvers)
Study: 28338504
Drug: Conventional group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional group (10 mL/kg predicted body weight, no positive end-expiratory pressure)
Study: 26657997
Drug: 15-mcg unadjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-mcg unadjuvanted clade 2 vaccine
Study: 26657997
Drug: 90-mcg unadjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90-mcg unadjuvanted clade 2 vaccine
Study: 26657997
Drug: 90-mcg dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90-mcg dosage in unprimed recipients
Study: 26657997
Drug: Alum-adjuvanted clade
Normalized name: alum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alum-adjuvanted clade 1 H5N1 vaccines
Study: 26657997
Drug: Non-adjuvanted clade
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted clade 1 H5N1 vaccines
Study: 22584689
Drug: Lornoxicam 16
Normalized name: Lornoxicam 16 mg prolonged-release oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 16 mg then 8 mg after 12 h
Study: 21097402
Drug: Routine western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine western medication
Study: 2148177
Drug: cetirizine 5
Normalized name: cetirizine 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: cetirizine 5 mg, 10 mg, or 20 mg
Study: 2148177
Drug: hydroxyzine 25
Normalized name: hydroxyzine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydroxyzine 25 mg
Study: 30632972
Drug: BlueStar mobile
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: BlueStar mobile app for 6 months (immediate treatment group)
Study: 25754454
Drug: Intravesical 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical 0.1% oxybutynin hydrochloride (10 ml, three times per day for 28 days)
Study: 25754454
Drug: Oral 5
Normalized name: Syringe Oral 5cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 5 mg oxybutynin hydrochloride (three times per day for 28 days)
Study: 25754454
Drug: Oral 5
Normalized name: Syringe Oral 5cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 5 mg oxybutynin hydrochloride
Study: 25031529
Drug: Alpha-blocker plus
Normalized name: ALPHA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-blocker plus antidiuretic agent
Study: 25031529
Drug: Alpha-blocker plus
Normalized name: ALPHA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-blocker plus anticholinergic agent
Study: 25031529
Drug: Alpha-blocker
Normalized name: ALPHA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-blocker
Study: 12412821
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 4 mg/5 min
Study: 12412821
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (all doses)
Study: 6388080
Drug: Noradrenaline (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline (8 mg in 100 ml cold saline)
Study: 9279213
Drug: Inhaled ET-1
Normalized name: isoetharine 1 % Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled ET-1 (doubling dose range, 0.96 to 15.36 nmol)
Study: 9279213
Drug: Methacholine (doubling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methacholine (doubling dose range, 0.33 to 21.0 mumol)
Study: 30457060
Drug: Gonadotrophin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotrophin-releasing hormone agonist (GnRHa)
Study: 3729714
Drug: Low-dose subcutaneous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose subcutaneous heparin therapy
Study: 25274610
Drug: Dasatinib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib (100 mg) alone
Study: 25274610
Drug: Dasatinib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib (100 mg) with 1500 mg BHCl after rabeprazole pretreatment
Study: 22462626
Drug: Vardenafil 5
Normalized name: vardenafil 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil 5 mg/day
Study: 22462626
Drug: Vardenafil 10
Normalized name: vardenafil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil 10 mg/day
Study: 22462626
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no PDE5 inhibitors)
Study: 12050248
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) at a dose of 12.5 microg/kg per day for 12 months